Nevirapine
- Generic Name
- Nevirapine
- Brand Names
- Viramune
- Drug Type
- Small Molecule
- Chemical Formula
- C15H14N4O
- CAS Number
- 129618-40-2
- Unique Ingredient Identifier
- 99DK7FVK1H
- Background
A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.
- Indication
For use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Study to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Rifabutin (MYCOBUTIN®) in HIV+ Patients
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 19
- Registration Number
- NCT02184078
Study of Nevirapine and Prednisone to Determine the Safety and Effectiveness in Preventing Nevirapine Associated Rash in Human Immunodeficiency Virus (HIV) Infected Patients
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 138
- Registration Number
- NCT02184299
Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine, Abacavir and Amprenavir in HIV-1 Infected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Naive Adults
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 8
- Registration Number
- NCT02182765
Effects of Nevirapine on the Steady State Pharmacokinetics of Fluconazole in HIV Positive Patients
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02181946
Efficacy of Nevirapine Compared to ZDV + 3TC Administered in Labor and Again at Postdelivery in HIV Positive Women
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2648
- Registration Number
- NCT02181933
Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (VIRAMUNE) and Ethinyl Estradiol/Norethindrone in HIV-1 Infected Women
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 14
- Registration Number
- NCT02182791
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
- First Posted Date
- 2014-04-17
- Last Posted Date
- 2019-04-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 11
- Registration Number
- NCT02116660
Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TB
- First Posted Date
- 2013-03-06
- Last Posted Date
- 2013-03-26
- Target Recruit Count
- 135
- Registration Number
- NCT01805258
- Locations
- 🇮🇳
All India Institute of Medical Sciences, New Delhi, India
A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral Therapy
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-02-12
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 60
- Registration Number
- NCT01789879
- Locations
- 🇺🇬
Infectious Diseases Institute, Kampala, Uganda
Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-01-21
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Centre Hospitalier Universitaire Saint Pierre
- Target Recruit Count
- 425
- Registration Number
- NCT01772940
- Locations
- 🇨🇬
Cliniques Universitaires de Lubumbashi, Lubumbashi, Katanga, Congo
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath